Use of alpha-blockers and the risk of hip/femur fractures
Use of alpha-blockers and the risk of hip/femur fractures
Objective: To study the association between use of ?-blockers and risk of hip/femur fractures.
Design: Population-based case–control study.
Setting: General Practice Research Database.
Subjects: Cases were defined as men, aged 40 years and older with a first diagnosis for hip/femur fracture. Controls were matched 1 : 1 on gender, year of birth and general practitioner-practice.
Results: In all, 4571 cases and an equal number of controls were identified. Current use of ?-blockers (prazosin, doxazosin, indoramin, terazosin, alfuzosin and tamsulosin) was compared with non-use of ?-blockers. Current use of ?-blockers on the index date was associated with an increased risk of hip/femur fracture [adjusted odds ratio (OR) 1.9, 95% confidence interval (CI): 1.1–3.0] in the overall analysis. The effect was particularly strong for first prescriptions within a treatment episode (adjusted OR 5.1, 95% CI: 1.0–31.7) and during the first month of treatment (adjusted OR 4.1, 95% CI: 0.7–23.9). Stratification according to indication of use showed that current use of ?-blockers was not associated with hip/femur fracture in men with a diagnosis of benign prostatic hyperplasia (adjusted OR 1.0, 95% CI: 0.4–2.5), but was associated in men who used ?-blockers for cardiovascular disease (adjusted OR 2.8, 95% CI: 1.4–5.4).
Conclusion: Current use of ?-blockers was associated with an increased risk of hip/femur fracture and with the start of a new treatment episode. The effect seemed to be confined to patients who used ?-blockers for cardiovascular disease. Caution with respect to first-dose effects related to the initiation of a new episode of ?-blocker treatment is advised.
adrenergic alpha-antagonists, case–control studies, hip fractures, pharmacoepidemiology
548-554
Souverein, P.C.
44dfc72c-9a33-4ab8-bce5-574052a8dc18
Van Staa, T.P.
31b8bfb4-4e1b-4a48-a5a6-90ca601b94af
Egberts, A.C.G.
eb765fde-f548-4c1a-8683-5480573617d5
De la Rosette, J.J.M.C.H.
167dde63-8d79-4cdd-aa40-cbdc47a9f87e
Cooper, C.
e05f5612-b493-4273-9b71-9e0ce32bdad6
Leufkens, H.G.M.
04854167-bea6-4508-a8e2-aeb920a2d6b1
2003
Souverein, P.C.
44dfc72c-9a33-4ab8-bce5-574052a8dc18
Van Staa, T.P.
31b8bfb4-4e1b-4a48-a5a6-90ca601b94af
Egberts, A.C.G.
eb765fde-f548-4c1a-8683-5480573617d5
De la Rosette, J.J.M.C.H.
167dde63-8d79-4cdd-aa40-cbdc47a9f87e
Cooper, C.
e05f5612-b493-4273-9b71-9e0ce32bdad6
Leufkens, H.G.M.
04854167-bea6-4508-a8e2-aeb920a2d6b1
Souverein, P.C., Van Staa, T.P., Egberts, A.C.G., De la Rosette, J.J.M.C.H., Cooper, C. and Leufkens, H.G.M.
(2003)
Use of alpha-blockers and the risk of hip/femur fractures.
Journal of Internal Medicine, 254 (6), .
(doi:10.1111/j.1365-2796.2003.01227.x).
Abstract
Objective: To study the association between use of ?-blockers and risk of hip/femur fractures.
Design: Population-based case–control study.
Setting: General Practice Research Database.
Subjects: Cases were defined as men, aged 40 years and older with a first diagnosis for hip/femur fracture. Controls were matched 1 : 1 on gender, year of birth and general practitioner-practice.
Results: In all, 4571 cases and an equal number of controls were identified. Current use of ?-blockers (prazosin, doxazosin, indoramin, terazosin, alfuzosin and tamsulosin) was compared with non-use of ?-blockers. Current use of ?-blockers on the index date was associated with an increased risk of hip/femur fracture [adjusted odds ratio (OR) 1.9, 95% confidence interval (CI): 1.1–3.0] in the overall analysis. The effect was particularly strong for first prescriptions within a treatment episode (adjusted OR 5.1, 95% CI: 1.0–31.7) and during the first month of treatment (adjusted OR 4.1, 95% CI: 0.7–23.9). Stratification according to indication of use showed that current use of ?-blockers was not associated with hip/femur fracture in men with a diagnosis of benign prostatic hyperplasia (adjusted OR 1.0, 95% CI: 0.4–2.5), but was associated in men who used ?-blockers for cardiovascular disease (adjusted OR 2.8, 95% CI: 1.4–5.4).
Conclusion: Current use of ?-blockers was associated with an increased risk of hip/femur fracture and with the start of a new treatment episode. The effect seemed to be confined to patients who used ?-blockers for cardiovascular disease. Caution with respect to first-dose effects related to the initiation of a new episode of ?-blocker treatment is advised.
This record has no associated files available for download.
More information
Published date: 2003
Keywords:
adrenergic alpha-antagonists, case–control studies, hip fractures, pharmacoepidemiology
Identifiers
Local EPrints ID: 25991
URI: http://eprints.soton.ac.uk/id/eprint/25991
ISSN: 0954-6820
PURE UUID: 0d7c3500-06c2-49e9-91e2-73d41ec18fff
Catalogue record
Date deposited: 24 Apr 2006
Last modified: 18 Mar 2024 02:44
Export record
Altmetrics
Contributors
Author:
P.C. Souverein
Author:
T.P. Van Staa
Author:
A.C.G. Egberts
Author:
J.J.M.C.H. De la Rosette
Author:
H.G.M. Leufkens
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics